Fosfomycin

• Description:

  Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria[1][2].

• Product Name Alternative:

  MK-0955

• UNSPSC:

  12352005

• Target:

  Antibiotic; Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/fosfomycin.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@@H]1O[C@@H]1P(O)(O)=O

• Molecular Formula:

  C3H7O4P

• Molecular Weight:

  138.06

• References & Citations:

  [1]Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29 (2) :321-47.|[2]Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel) . 2017 Oct 31. 6 (4) :24.|[3]Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5 (12) :941-50.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Infect Genet Evol. 2025 Sep:133:105780.|Microb Pathog. 2025 Oct 25.|Microbiol Spectr. 2025 Sep 2;13 (9) :e0152125.|ACS Infect Dis. 2024 Aug 9;10 (8) :2961-2977.|Antibiotics (Basel) . 2021 Sep 14;10 (9) :1110.|bioRxiv. 2024 May 10.|bioRxiv. 2025 January 19.|J Antibiot (Tokyo) . 2025 Mar;78 (4) :265-273.|MedComm (2020) . 2025 Jan 8;6 (1) :e70046.|Molecules. 2025 Mar 9;30 (6) :1224.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Front Cell Infect Microbiol. 2019 Jul 15:9:253.|J Med Microbiol. 2019 Mar;68 (3) :493-502.

• CAS Number:

  23155-02-4